HImplementation of H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act)
Draft legislation relating to economic activity in Puerto Rico S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit manag
S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Part D policy issues including non-interference and rebates policy issues
Part B reform including MedPAC recommendations and other policy issues
Drug cost and pricing policy issues
Transparency policy issues
Alternative payment models policy issues
Value-based purchasing arrangements policy issues
Anti-Kickback Statute policy issues
Center for Medicare and Medicaid Innovation (CMMI) policy issues
Medicaid rebates and waiver policy issues
Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018
Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P) S. 3158: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2019, and for other purposes Trade Agreements and related policy issue
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Canada intellectual property and market access policy issues
NAFTA policy issues
Korea Trade Agreement (KORUS) policy issues H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements
H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms
S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements
S. 974 Amendment: Hatch-Waxman Integrity Act of 2018 - Provisions related to inter partes review process
S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms
S. 2601: BIG Data for IP Act - Provisions related to fee-setting authority
Biopharmaceutical innovation and patent policy issues
Patent litigation reform issues and issues related to post-grant proceeding at the PTO
Draft legislation related to notification of agreements to the FTC and DOJ
Bayh-Dole march-in rights policy issues H.R. 2212: CREATES Act of 2017 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program
H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 - Provisions related to use of unapproved medical products by patients with a terminal illness
H.R. 5353; Leonard Lance, Eliminating Opioid Infectious Diseases Act of 2018 
H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program
H.R. 5687: SOUND Disposal and Packaging Act - To require improved packaging and disposal methods with respect to certain drugs
H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program
H.R. 6142: Reducing Drug Waste Act of 2018 - Action plan and report on vial size waste
S. 204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness
S. 974: CREATES Act of 2017 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pri
S. 2312: HELP Act - Provisions related to 340B progr
S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B prog
S. 2589: Comprehensive Opioid Recovery Centers Act of 2018 - Provisions related to CDC infection surveillance and other funding
Drug cost and pricing policy issues
Transparency policy issues
Drug importation and counterfeiting policy issues
Prescription drug take back and secure disposal policy issues
Policy issues related to prescription drug abuse and opioids
Expanded access policy issues
Generic drug approval process policy issues
Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors
Risk Evaluation and Mitigation Strategy (REMS) policy issues
Limited distribution systems in the pharmaceutical supply chain policy issues
FDA modernization policy issues
340B drug discount program policy issues
21st Century Cures Act (Public Law 114-255) - Provisions related to biopharmaceutical discovery, development, delivery, and transparency
Senate HELP Committee Innovation Agenda - Provisions related to biopharmaceutical discovery and development of FDA policy
Patient assistance program policy issues
Biosimilar approval and reimbursement policy issues
Cancer drug vial size policy issue
Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid BUD - Budget/Appropriations TRD - Trade (domestic/foreign) CPT - Copyright/Patent/Trademark HCR - Health Issues
14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S.
ABBVIE, INC.
1399 New York Avenue NW, Suite 600, Washington, DC, 20005, US
DANIEL BACHNER STEPHEN SCANGO COURTNEY PIRON STEPHEN SCANGO DANIEL BACHNER COURTNEY PIRON HAYDEN RHUDY KENNEDY (Sen Orrin Hatch, 1/2011-9/2013 Senior Health Policy Advisor: Sen Mike Enzi, Senate HELP Cmt. 11/2007-1/2011 Research Asst, Prof Staff Member; Sen Issakson, 3/2005-11/2007; Staff Asst, Asst Sched; Health LC) DANIEL BACHNER STEPHEN SCANGO COURTNEY PIRON STEPHEN SCANGO COURTNEY PIRON DANIEL BACHNER DANIEL BACHNER STEPHEN SCANGO COURTNEY PIRON STEPHEN SCANGO DANIEL BACHNER COURTNEY PIRON HAYDEN RHUDY KENNEDY (Sen Orrin Hatch, 1/2011-9/2013 Senior Health Policy Advisor: Sen Mike Enzi, Senate HELP Cmt. 11/2007-1/2011 Research Asst, Prof Staff Member; Sen Issakson, 3/2005-11/2007; Staff Asst, Asst Sched; Health LC)
Sen Orrin Hatch, 1/2011-9/2013 Senior Health Policy Advisor: Sen Mike Enzi, Senate HELP Cmt. 11/2007-1/2011 Research Asst, Prof Staff Member; Sen Issakson, 3/2005-11/2007; Staff Asst, Asst Sched; Health LC Sen Orrin Hatch, 1/2011-9/2013 Senior Health Policy Advisor: Sen Mike Enzi, Senate HELP Cmt. 11/2007-1/2011 Research Asst, Prof Staff Member; Sen Issakson, 3/2005-11/2007; Staff Asst, Asst Sched; Health LC